



Objective: The aim of the present study was to determine the genotype association for al-
leles of class II human leukocyte antigens (HLA) in the DRB1* locus among blood donors 
at the Fundação Hemope (Brazil) infected by or immunized for the hepatitis B virus (HBV). 
Methods: A case-control study was performed, comprising a group of individuals infected 
by HBV and a control group of immunized individuals at a proportion of 1:4. Blood samples 
were taken for the HLA typing of the DRB1* locus. Univariate and multivariate analyses were 
performed for the assessment of associations between the categorical variables using the 
chi-squared test and Fisher’s exact test. Results: A total of 320 blood donors were analyzed 
(241 males [75%] and 79 females [25%] with a mean age of 39 years). The case group consisted 
of 64 HBV-infected donors and the control group was composed of 256 HBV-immunized 
donors. The multivariate analysis stratified by gender revealed that the DRB1*09 allele was 
associated with infected male donors (p = 0.016) and the DRB1*08 allele was associated with 
infected donors aged 39 years or younger (p = 0.031). Conclusion: The results of the present 
study reveal that younger blood donors and male blood donors who respectively exhibit the 
DRB1*08 and DRB1*09 alleles are more susceptible to intensification of HBV infection.
Keywords: HLA antigens; major histocompatibility complex; hepatitis; HLA and HBV 
infection.
RESUMO
Associação entre polimorﬁsmos HLA-DRB1* e infecção por hepatite 
B em uma população brasileira
Objetivo: O objetivo do presente estudo foi determinar a associação genotípica dos alelos de 
classe II dos antígenos leucocitários humanos (HLA) presentes no locus DRB1* entre doado-
res de sangue da Fundação Hemope (Brasil), infectados pelo ou imunizados contra o vírus da 
hepatite B (HBV). Métodos: Estudo caso-controle foi realizado com um grupo de indivíduos 
infectados pelo HBV e um grupo controle composto de indivíduos imunizados na proporção 
de 1:4. Amostras de sangue foram coletadas para a tipagem HLA do locus DRB1*. Análises 
univariada e multivariada foram realizadas para a avaliação de associações entre as variáveis 
categóricas pelo teste do qui-quadrado e teste exato de Fisher. Resultados: Um total de 320 
doadores de sangue foram analisados (241 homens [75%] e 79 do sexo feminino [25%], com 
idade média de 39 anos). O grupo de casos consistiu de 64 doadores infectados pelo HBV e o 
grupo controle foi composto de 256 doadores imunes ao HBV. A análise multivariada estra-
tificada por sexo revelou que o alelo DRB1*09 foi associado com os doadores infectados do 
sexo masculino (p = 0,016) e do alelo DRB1*08 foi associado com os doadores infectados com 
idade entre 39 anos ou mais jovens (p = 0,031). Conclusão: Os resultados do presente estudo 
revelam que doadores de sangue mais jovens e doadores de sangue do sexo masculino que 
exibem, respectivamente, os alelos DRB1*08 e DRB1*09, são mais suscetíveis à cronificação 
da infecção pelo HBV.
Unitermos: Antígenos HLA; complexo maior de histocompatibilidade; hepatites; HLA; 
infecção por HBV.
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INTRODUCTION
The reason why allelic diversity in the genes of the major 
histocompatibility complex has been conserved through-
out the evolution of the human species has not yet been 
clarified. Thus, the role of polymorphisms in these mol-
ecules in the determination of susceptibility or resis-
tance to disease has merited attention1. The tracking of 
histocompatibility alleles in different ethnic groups from 
different geographic regions indicates that gene conver-
sion and mutation are the main generating mechanisms 
of allelic diversity on the population level, and that sites 
of greater polymorphism are found in the regions of the 
α and β chains, which are in contact with antigenic pep-
tides2. Allelic diversity is believed to be generated from 
interactions with pathogenic agents3,4. Indeed, studies on 
the characteristics of patients may contribute toward the 
understanding of the association between human leuko-
cyte antigens (HLA) and susceptibility to infections, such 
as by the hepatitis B virus (HBV)5,6.
The highly polymorphic HLA antigens are of key im-
portance in the activation of the immune response against 
viruses through their enormous capacity of attracting and 
binding viral peptides. It is estimated that one cell has 
100,000 to 300,000 class I or II HLA molecules on its sur-
face7. As all HLA molecules expressed on the cell surface 
contain peptides, each cell can have thousands of peptides. 
The peptide-HLA bond is not as strong as the antigen-an-
tibody bond, but has slow dissociation constants, lasting 
hours to days, which are sufficient to remain linked to the 
viral peptide until they are presented to the CD4+ T lym-
phocytes, culminate in the activation and amplification of 
the immune response7.
The binding of particular peptides is a crucial phe-
nomenon to the elimination of the aggressive agent7. 
Previously attributed only to the rejection of grafts, a 
number of studies have demonstrated associations be-
tween the development of autoimmune endocrine dis-
eases and the genes of the histocompatibility system8. In 
recent years, there has been an intensification of studies 
on the HLA function in the presentation of viral anti-
gens to CD4+ and CD8+ T lymphocytes, aiming to elimi-
nate viral agents7. In Spain, Cotrina et al.9 analyzed the 
HLA-DRB1 genotype in patients with acute and chronic 
hepatitis caused by HBV and found that the HLA-DRB1* 
1301 and DRB1* 1302 alleles were associated with the 
resolution of the infection.
Considering the need to better understand the HLA 
profile of HBV infection in northeastern Brazil, the aim 
of the present study was to determine the genotype as-
sociation for alleles of class II HLA in the DRB1* locus in 
blood donors at the Hematology and Hemotherapy Foun-
dation of the state of Penambuco (Fundação Hemope, 
Brazil) infected and immunized by HBV.
METHODS
A case-control study nested in a cohort of blood donors at 
the Fundação Hemope was performed between December 
2008 and December 2009. The donors were analyzed con-
secutively based on demand. Those who tested positive for 
HBsAg or anti-HBc during routine donations were asked 
to perform confirmatory tests with another blood sample 
and were thus denominated return donors. On their re-
turn, all donors were asked to read and sign an informed 
consent. All personal data of interest to the study, such as 
age, gender, and donation date, were gathered during the 
initial donation and entered the database. This study was 
approved by the Human Research Ethics Committee of the 
Fundação Hemope.
Male and female blood donors between 18 and 65 years 
of age were included in the study. The case group was com-
posed of donors positive for anti-HBc and HBsAg mark-
ers. The control group comprised individuals immunized 
for HBV who were positive for anti-HBc and anti-HBs 
markers. Donors positive for anti-HCV, anti-HIV, anti-
HTLV, or Chagas disease, and those who failed to return 
for the confirmatory test were excluded from the study.
The determination of serum HBV markers was per-
formed using immunoenzymatic assays for the qualitative 
detection of HBsAg (MUREX, HBsAg version 3, Abbott) 
and anti-HBc (ORTHO, HBc ELISA Test System), as well as 
for the quantitative detection of anti-HBs (AxSYM AUSAB, 
Abbott), following the manufacturers’ instructions.
Besides the blood sample for donation, 5 mL of venous 
blood were collected for subsequent HLA typing. The 
samples were sent to the Molecular Biology Laboratory at 
Hemope for the extraction of genomic DNA, which was 
frozen and stored at - 80º C until HLA DRB1* typing.
The polymerase chain reaction/specific oligonucle-
otide sequence (PCR-SSO) method was used with the 
RSSO2B1 from One Lambda. The analysis of the material 
obtained in the hybridization phase was performed in a 
Labscan 100 cytometer (LUMINEX). The interpretation of 
the results was performed with the appropriate software 
provided by One Lambda10.
The database was constructed using the Statistical Pack-
age for the Social Sciences, version 13.1 for Windows (SPSS 
Inc. – Chicago, IL, 2005). The characteristics of the case and 
control groups (gender and age) were described in absolute 
and relative frequencies. Moreover, all 78 possible HLA-
DRB1* types in pairs of alleles were described in absolute 
and relative frequencies for the case and control groups. 
Univariate and multivariate analyses were performed for 
the assessment of associations between the categorical 
variables using the chi-squared test and Fisher’s exact test. 
The univariate analysis considered all 13 DRB1* alleles in 
a contingency table, determining the presence or absence 
of each allele in the case and control groups (Table 1). 
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The multivariate analysis involved those variables that ex-
hibited an association with the presence of HBV infection 
in the univariate analysis with a p-value ≤ 0.20. The multi-
variate logistic regression of associations between HBV in-
fection and the DRB1* variables selected in the univariate 
HLA-DRB1* Cases Controls X2 p-value
DRB1*01
Absence 49 (76.6%) 207 (80.9%)
Presence 15 (23.4%) 49 (19.1%) 0.591 0.442
DRB1*03
Absence 53 (82.8%) 209 (81.6%)
Presence 11 (17.2%) 47 (18.4%) 0.047 0.828
DRB1*04
Absence 52 (81.3%) 206 (80.5%)
Presence 12 (18.8%) 50 (19.5%) 0.020 0.888
DRB1*07
Absence 49 (76.6%) 205 (80.1%)
Presence 15 (23.4%) 51 (19.9%) 0.387 0.534
DRB1*08
Absence 49 (76.6%) 220 (85.9%)
Presence 15 (23.4%) 36 (14.1%) 3.359 0.067
DRB1*09
Absence 57 (89.1%) 243 (94.9%)
Presence 07 (10.9%) 13 (5.1%) 3.0 0.083
DRB1*10
Absence 63 (98.4%) 247 (96.5%)
Presence 01 (1.6%) 09 (3.5%) 0.645 0.422
DRB1*11
Absence 51 (79.7%) 195 (76.2%)
Presence 13 (20.3%) 61 (23.8%) 0.356 0.551
DRB1*12
Absence 63 (98.4%) 240 (93.8%)
Presence 01 (1.6%) 16 (6.3%) 2.236 0.135
DRB1*13
Absence 52 (81.3%) 199 (77.7%)
Presence 12 (18.8%) 57 (22.3%) 0.374 0.541
DRB1*14
Absence 58 (90.6%) 239 (93.4%)
Presence 06 (9.4%) 17 (6.6%) 0.574 0.449
DRB1*15
Absence 55 (85.9%) 199 (77.7%)
Presence 09 (14.1%) 57 (22.3%) 2.105 0.147
DRB1*16
Absence 56 (87.5%) 232 (90.6%)
Presence 08 (12.5%) 24 (9.4%) 0.556 0.456
Table 1 – Association between the 78 possible combinations 
found among the HLA-DRB1* and HBV infection
analysis was stratified by gender and age. The magnitudes 
of these associations were estimated as odds ratios (OR), 
using 95% confidence intervals (CI). All p-values less than 
0.05 in the multivariate analysis were indicative of statisti-
cal significance.
RESULTS
Among the 320 blood donors, 241 (75%) were male and 
79 (25%) were female. The mean age was 39 years, ranging 
from 18 to 65 years. The case group was composed of 64 
donors infected by HBV (positive anti-HBc and HBsAg), 
and the control group was composed of 256 HBV-immu-
nized donors (positive anti-HBc and anti-HBs). No demo-
graphic differences were observed between the two groups. 
The univariate analysis revealed that HBV infection was 
not significantly associated with gender (OR: 1.021; 95% 
CI: 0.542-1.924; p = 0.948) or age (OR: 0.983; 95% CI: 
1.009- 5.94; p = 0.204). The most frequent combinations in 
the case group were DRB1*03*08 and DRB1*04*07 (6.3%). 
The DRB1*11*13 combination was more frequent in the 
control group (4.3%). However, these differences did not 
achieve statistical significance (p = 0.314).
The univariate analysis revealed that the following 
DRB1* alleles were associated to the infected donors 
(case group) at a level of significance of p ≤ 0.2: DRB1*08 
(p = 0.067), DRB1*09 (p = 0.083), DRB1*12 (p = 0.135), 
and DRB1*15 (p = 0.147) (Table 1). The multivariate 
analysis stratified by gender revealed that the DRB1*09 
was associated with infected donors of the male gender 
(OR: 4.20; 95% CI: 1.30 to 13.60; p = 0.016) (Table 2). 
The multivariate analysis stratified by age revealed that 
DRB1*08 was more frequent in infected donors aged 
39 years or younger (OR: 2.54; 95% CI: 1.09 to 5.94; 
p = 0.031) (Table 3). 
DISCUSSION
The susceptibility to persistence or resolution of HBV 
infection depends on the immune response and may be 
explained by immunogenetic factors in the host11-14. Stud-
ies on the correlation between HLA and HBV infection 
have been performed for a number of years12,15,16. The tra-
ditional serological methods used in HLA typing in some 
investigations are imprecise and have become obsolete. In 
the present study, HLA-DRB1 alleles were investigated us-
ing PCR-SSO on blood donors infected by HBV and those 
immune to the virus in order to determine possible asso-
ciations. 13 HLA-DRB1 alleles were detected, which agrees 
with the number reported by Ye-Gui Jiang et al.17.
Although the presence of a particular HLA allele alone 
is not sufficient to define the immune status against HBV, 
it has been demonstrated that in certain groups, such as 
males or elder individuals, some genotypes are more prev-
alent in chronically infected individuals. In the present 
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study, HBV infection in men and individuals under 39 
years of age was associated with the HLA-DRB1*09 and 
DRB1*08 alleles, respectively.
It should be stressed that differences in allelic frequen-
cies may occur between different populations, which does 
not allow for the generalization of the present results. 
Thus, studies involving specific populations, especially 
mixed-raced, such as that found in Brazil, are needed to 
determine whether the HLA associations are the same 
described in the literature, and whether there are new 
associations9. There are different relationships between 
polymorphic HLA genes and HBV infection in different 
populations, which implies that different HLA molecules 
could exhibit different HBV epitopes in order to induce 
an efficacious immune response6,18. Indeed, a study con-
ducted in China19 reported that the DRB1*06, DRB1*08 
and DRB1*16 alleles may be related to the intensification 
of HBV alleles in comparison to other HLA-DRB1 alleles. 
The HLA-DRB1* locus is an important factor associated 
with the evolution of HBV infection and should be the 
subject of further studies on the pathogenesis of the chro-
nicity of infection by this agent6,20.
The present study revealed limited power for the de-
tection of associations with low-frequency alleles, and the 
associations found cannot be applied to all populations. 
The study of ethnically diverse populations and greater 
knowledge of the association between the HLA system and 
HBV infection will allow for the design of strategies for the 
identification of risk groups. In the near future, the type 
of clinical manifestation of the virus may be predictable, 
which will allow for orientation of the use of medications 
based on the pharmacogenomic profile of patients as well 
as the establishment of measures for preventing the occur-
rence of HBV infection.
Sex Cases Controls OR IC 95% p-value
Female
DRB1*08
Absence 12 (75%) 54 (85.7%) 1.0
Presence 04 (25%) 09 (14.3%) 1.94 0.48-7.76 0.348
DRB1*09  
Absence 15 (93.8%) 57 (90.5%) 1.0
Presence 01 (6.3%) 06 (9.5%) 0.62 0.06-5.81 0.682
DRB1*12
Absence 16 (100%) 61 (96.8%) 1.0
Presence 00 (00%) 02 (3,2%) 0.00 0.00-0.00 0.999
DRB1*15
Absence 13 (81.3%) 51 (81%) 1.0
Presence 03 (18.8%) 12 (19%) 1.05 0.24-4.60 0.941
Male
DRB1*08
Absence 37 (77.1%) 166 (86%) 1.0
Presence 11 (22.9%) 27 (14%) 1.80 0.80-4.06 0.153
DRB1*09
Absence 42 (87.5%) 186 (96.4%) 1.0
Presence 06 (12.5%) 07 (3.6%) 4.20 1.30-13.60 0.016
DRB1*12
Absence 47 (97.9%) 179 (92.7%) 1.0
Presence 01 (2.1%) 14 (7.3%) 0.30 0.03-2.43 0.264
DRB1*15
Absence 42 (87.5%) 148 (76.7%) 1.0
Presence 06 (12.5%) 45 (23.3%) 0.46 0.18-1.18 0.110
Table 2 – Multivariate logistic regression of association between HBV infection and variables of the DRB1* locus 
(*08,*09,*12,*15) stratiﬁed by gender
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CONCLUSIONS 
Based on the results of the present study, preventive mea-
sures are suggested for infection by HBV, especially for 
young individuals of the male gender in Northeastern Bra-
zil with the HLA-DRB1*08 or DRB1*09 profile, respec-
tively. Studies with other samples should be performed in 
order to confirm these results or to reveal other genetic 
determinants associated with susceptibility or resistance to 
infection by HBV.
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